Survival results of hepatectomy followed by adjuvant chemotherapy with three months of capecitabine plus oxaliplatin for colorectal cancer liver metastases: A multicenter phase II study.

866Background: Hepatic resectionis one of the treatment strategies for resectablecolorectal cancer liver metastases (CLM). The role of neoadjuvant and adjuvant chemotherapyin the management of initially resectableCLM is still unclear. Adjuvant chemotherapyconsisting of capecitabineplus oxaliplatin(CapeOx) appears to be equivalent to FOLFOXin patients with stage III colon cancer. Furthermore, the IDEA collaboration reported that adjuvant chemotherapywith the three months of CapeOx after curative resectionfor stage III colon cancer has equivalent efficacy to adjuvant chemotherapyfor 6 months. We conducted a multi-institutional, single-arm, phase II trial to confirm the feasibility of the three months of adjuvantCapeOx for post curative resectionof CLM. Methods: Patients received one course of capecitabinefollowed by four courses of CapeOx for a total five courses (15 weeks) as adjuvant chemotherapyafter curative resectionof CLM. Oral capecitabinewas given with 1,000 mg/m2 twice daily for 2 ...